Banking on Botox No Concern for Allergan Inc. CEO

Allergan Inc (AGN.N) is not worried about over-reliance on sales of its flagship Botox drug, the company's chief said, citing extensive safety data and supply reserves of the injectable medicine. The wrinkle-smoothing treatment recently won U.S. approval to treat migraine headaches and overactive bladders, positioning it for an even bigger chunk of Allergan's sales than the 30 percent it commands now. Allergan Chief Executive David Pyott told Reuters he expects Botox sales to exceed $1 billion apiece for cosmetic and therapeutic use. Allergan forecasts nearly $1.6 billion in Botox sales this year.

Back to news